The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 10 06 2020
revised: 04 11 2020
accepted: 19 11 2020
pubmed: 29 11 2020
medline: 21 10 2021
entrez: 28 11 2020
Statut: ppublish

Résumé

Salivary duct carcinoma (SDC) is a high-grade salivary gland neoplasm. It may occur de novo or secondarily from pleomorphic adenoma (ex-PA), with secondary development accounting for more than 50% of the cases. In recent years, the expression of tyrosine kinase receptor B (TrkB), which is in the same family as HER2, has been confirmed in various types of carcinomas. However, there are a few studies on SDC. In order to examine the expression and role of TrkB in SDC, we investigated it. Immunohistochemistry was used to detect the expression of TrkB and its ligands, brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4) in 20 patients with SDC. The mRNA levels of TrkB, BDNF, and NT-4 were analyzed using quantitative polymerase chain reaction. TrkB was negative in 10 cases and positive in 10 cases, BDNF was negative in 11 cases and positive in 9 cases, and NT-4 was positive in all cases. There was a high number of TrkB-positive cases in the pT4 group and The H-score of TrkB was also significantly higher in the stage III and IV groups. There was a high number of BDNF-positive cases in the ex-PA group and Histo-score of BDNF had a trend of high expression in ex-PA. There were no significant differences or correlations in mRNA expression. Our results suggest that TrkB may be involved in SDC tumor growth.

Identifiants

pubmed: 33248386
pii: S1092-9134(20)30219-7
doi: 10.1016/j.anndiagpath.2020.151673
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Brain-Derived Neurotrophic Factor 0
Membrane Glycoproteins 0
Nerve Growth Factors 0
RNA, Messenger 0
Receptor Protein-Tyrosine Kinases EC 2.7.10.1
Receptor, trkB EC 2.7.10.1
tropomyosin-related kinase-B, human EC 2.7.10.1
neurotrophin 4 P658DCA9XD

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

151673

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Yusuke Kondo (Y)

Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan. Electronic address: kondou@tokai-u.jp.

Kenichi Hirabayashi (K)

Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

Joaquim Carreras (J)

Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

Keiichi Tsukinoki (K)

Department of Oral Science, Graduate School of Dentistry, Kanagawa Dental University, Yokosuka, Kanagawa 238-8580, Japan.

Yoshihide Ota (Y)

Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

Kenji Okami (K)

Department of Otolaryngology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

Naoya Nakamura (N)

Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH